Peter Sander
Overview
Explore the profile of Peter Sander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
2035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jung E, Griesser T, Costafrolaz J, Duverger O, Mattenberger Y, Dittmann S, et al.
Angew Chem Int Ed Engl
. 2024 Nov;
64(7):e202419095.
PMID: 39584779
Peripheral modification is often the main approach to optimize natural products for improved biological activity or desired physicochemical properties. This procedure inevitably increases molecular weight, often accompanied by undesired increased...
2.
Negatu D, Aragaw W, Gebresilase T, Paruchuri S, Kaya F, Shin S, et al.
Antimicrob Agents Chemother
. 2024 Nov;
69(1):e0104624.
PMID: 39565116
β-Lactams present several desirable pharmacodynamic features leading to the rapid eradication of many bacterial pathogens. Imipenem (IPM) and cefoxitin (FOX) are injectable β-lactams recommended during the intensive treatment phase of...
3.
Dharuman S, Phelps G, Dunn C, Wilt L, Murphy P, Lee R, et al.
J Antibiot (Tokyo)
. 2024 Oct;
78(2):140.
PMID: 39394258
No abstract available.
4.
Dharuman S, Phelps G, Dunn C, Wilt L, Murphy P, Lee R, et al.
J Antibiot (Tokyo)
. 2024 Jun;
77(9):577-588.
PMID: 38890386
Spectinomycin is an aminocyclitol antibiotic with a unique ribosomal binding site. Prior synthetic modifications of spectinomycin have enhanced potency and antibacterial spectrum through addition at the 6'-position to produce trospectomycin...
5.
Phelps G, Cheramie M, Fernando D, Selchow P, Meyer C, Waidyarachchi S, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(2):e2314101120.
PMID: 38165935
(), a nontuberculous mycobacterial (NTM) species, is an emerging pathogen with high intrinsic drug resistance. Current standard-of-care therapy results in poor outcomes, demonstrating the urgent need to develop effective antimycobacterial...
6.
Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species
Jung E, Kraimps A, Dittmann S, Griesser T, Costafrolaz J, Mattenberger Y, et al.
Chembiochem
. 2023 Sep;
24(24):e202300570.
PMID: 37728121
Fidaxomicin (Fdx) is a natural product antibiotic with potent activity against Clostridioides difficile and other Gram-positive bacteria such as Mycobacterium tuberculosis. Only a few Fdx derivatives have been synthesized and...
7.
Dailler D, Dorst A, Schafle D, Sander P, Gademann K
Commun Chem
. 2023 Jan;
4(1):59.
PMID: 36697765
Fidaxomicin (FDX) is a marketed antibiotic for the treatment of Clostridioides difficile infections (CDI). Fidaxomicin displays antibacterial properties against many Gram-positive bacteria, yet the application of this antibiotic is currently...
8.
Lore N, Saliu F, Spitaleri A, Schafle D, Nicola F, Cirillo D, et al.
Eur Respir J
. 2022 Oct;
60(6).
PMID: 36265879
No abstract available.
9.
Schulthess B, Akdogan Kittana F, Homke R, Sander P
Antimicrob Agents Chemother
. 2022 Apr;
66(5):e0234621.
PMID: 35420492
Bedaquiline and clofazimine are increasingly used to treat infections with Mycobacterium abscessus. We determined distributions of MICs by broth microdilution for bedaquiline and clofazimine for 61 M. abscessus clinical isolates...
10.
Zurcher K, Reichmuth M, Ballif M, Loiseau C, Borrell S, Reinhard M, et al.
Lancet Microbe
. 2022 Mar;
2(7):e320-e330.
PMID: 35252901
Background: Drug resistance threatens global tuberculosis control. We aimed to examine mortality in patients with tuberculosis from high-burden countries, according to concordance or discordance of results from drug susceptibility testing...